Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference

   Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual
                              Growth Conference

PR Newswire

MALVERN, Pa., Dec. 7, 2012

MALVERN, Pa., Dec. 7, 2012 /PRNewswire/ --Auxilium Pharmaceuticals, Inc.
(Nasdaq: AUXL) today announced that executive management will participate in
the Oppenheimer Annual Growth Conference to be held December 12-13, 2012 at
the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief Executive
Officer and President, is scheduled to present an overview of the Company and
its product pipeline at 2:10 p.m. ET on Thursday, December 13, 2012. 

(Photo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

The presentation will also be webcast on the "For Investors" section of the
Auxilium website under the "Events" tab on December 13, 2012. The
presentation slides to be used will be available on the "For Investors"
section of the Auxilium website under the "Presentations" tab on December 13,
2012. To access the live webcast, please log on to Auxilium's website
approximately fifteen minutes prior to the presentation to register and
download any necessary audio software. The presentation replay will be
available for ninety days after the event. 

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum)
for the treatment of adult Dupuytren's contracture patients with a palpable
cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S. Ferring
International Center S.A. markets Testim in certain countries of the EU and
Paladin Labs Inc. markets Testim in Canada. Pfizer has marketing rights for
XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46
countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation
has development and commercial rights for XIAFLEX in Japan; and Actelion
Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment
of Peyronie's disease was submitted to the FDA in November 2012.
Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of
development for the treatment of Frozen Shoulder syndrome (adhesive
capsulitis) and phase Ib of development for the treatment of cellulite
(edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue
additional indications for CCH. For additional information, visit
http://www.auxilium.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995

This release contains "forward-looking-statements" within the meaning of The
Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Oppenheimer Annual Growth
Conference; and products in development for Peyronie's disease, Frozen
Shoulder syndrome and cellulite; and all other statements containing
projections, statements of future performance or expectations, our beliefs or
statements of plans or objectives for future operations (including statements
of assumption underlying or relating to any of the foregoing). Forward-looking
statements can generally be identified by words such as "believe," "appears,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and other words and terms of similar meaning in
connection with any discussion of projections, future performance or
expectations, beliefs, plans or objectives for future operations (including
statements of assumption underlying or relating to any of the foregoing).
Actual results may differ materially from those reflected in these
forward-looking statements due to various factors, including further
evaluation of clinical data, results of clinical trials, decisions by
regulatory authorities as to whether and when to approve drug applications,
and general financial, economic, regulatory and political conditions affecting
the biotechnology and pharmaceutical industries and those discussed in
Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the
year ended December 31, 2011, and Form 10-Q for the quarter ended September
30, 2012, which are on file with the Securities and Exchange Commission (the
"SEC") and may be accessed electronically by means of the SEC's home page on
the Internet at http://www.sec.gov or by means of Auxilium's home page on the
Internet at http://www.Auxilium.com under the heading "For Investors -- SEC
Filings." There may be additional risks that Auxilium does not presently know
or that Auxilium currently believes are immaterial which could also cause
actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans
or forecasts of future events and views as of the date of this release.
Auxilium anticipates that subsequent events and developments will cause
Auxilium's assessments to change. However, while Auxilium may elect to update
these forward-looking statements at some point in the future, Auxilium
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Auxilium's assessments as
of any date subsequent to the date of this release.

For More Information, Contact:
James E. Fickenscher / CFO     William Q. Sargent, Jr. / V.P., IR
Auxilium Pharmaceuticals, Inc. Auxilium Pharmaceuticals, Inc.
(484) 321-5900                 (484) 321-5900
jfickenscher@auxilium.com      wsargent@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com
 
Press spacebar to pause and continue. Press esc to stop.